Caplin Point Laboratories Ltd Stock Price Today (NSE: CAPLIPOINT)
Fundamental Score
Caplin Point Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Caplin Point Laboratories Ltd share price today is ₹2516.80, down 0.77% on NSE/BSE as of 31 July 2026. Caplin Point Laboratories Ltd (CAPLIPOINT) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹20.13K (Cr). The 52-week high for CAPLIPOINT share price is ₹2699.00 and the 52-week low is ₹1500.30. At a P/E ratio of 31.39x, CAPLIPOINT is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 20.62% and a debt-to-equity ratio of 0.00.
Caplin Point Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Caplin Point Laboratories Ltd share price chart: -1.84% return over the past month. 52-week high ₹2699.00, 52-week low ₹1500.30.
Caplin Point Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2536.30 | ₹2538.00 | ₹2495.80 | ₹2516.80 | 52.77K (Cr) | |
| ₹2613.20 | ₹2638.40 | ₹2517.40 | ₹2536.30 | 82.63K (Cr) | |
| ₹2590.90 | ₹2642.40 | ₹2588.10 | ₹2613.20 | 86.49K (Cr) | |
| ₹2639.40 | ₹2675.00 | ₹2575.00 | ₹2588.30 | 1.07L (Cr) | |
| ₹2470.00 | ₹2652.00 | ₹2470.00 | ₹2621.40 | 3.54L (Cr) | |
| ₹2470.30 | ₹2515.10 | ₹2451.40 | ₹2467.10 | 70.84K (Cr) | |
| ₹2465.10 | ₹2545.30 | ₹2435.40 | ₹2486.60 | 70.62K (Cr) | |
| ₹2661.80 | ₹2661.80 | ₹2606.00 | ₹2608.00 | 53.13K (Cr) | |
| ₹2614.00 | ₹2684.20 | ₹2601.10 | ₹2649.20 | 68.21K (Cr) | |
| ₹2671.90 | ₹2671.90 | ₹2576.90 | ₹2614.20 | 71.09K (Cr) |
Caplin Point Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2652.00 | ₹2699.00 | ₹2435.40 | ₹2516.80 | -5.10% | |
| ₹2024.50 | ₹2675.00 | ₹1950.00 | ₹2626.00 | +29.71% | |
| ₹1710.50 | ₹2099.00 | ₹1710.50 | ₹2024.50 | +18.36% | |
| ₹1565.00 | ₹1799.80 | ₹1508.00 | ₹1709.00 | +9.20% | |
| ₹1680.00 | ₹1710.00 | ₹1500.30 | ₹1504.80 | -10.43% | |
| ₹1790.10 | ₹1939.00 | ₹1681.10 | ₹1700.10 | -5.03% | |
| ₹1840.10 | ₹1871.00 | ₹1672.00 | ₹1773.90 | -3.60% | |
| ₹1911.00 | ₹1992.10 | ₹1747.00 | ₹1838.10 | -3.81% | |
| ₹2032.80 | ₹2074.00 | ₹1879.20 | ₹1910.80 | -6.00% | |
| ₹1973.80 | ₹2086.90 | ₹1960.10 | ₹2032.80 | +2.99% | |
| ₹2098.60 | ₹2395.00 | ₹1949.50 | ₹1966.10 | -6.31% | |
| ₹2066.30 | ₹2235.00 | ₹1886.00 | ₹2098.60 | +1.56% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Caplin Point is a US generics ANDA approval machine, but faces execution risks and project delays.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search.
CORE STORY (THE REAL GAME)
Caplin Point is a play on high-margin, regulated-market generics, specifically targeting injectables and ophthalmics. The market narrative is about their ability to secure ANDA approvals and efficiently commercialize them in the US and other regulated markets.
- Acquisition of 10 ANDAs for injectables and ophthalmics
- Strong Q3 FY26 EBITDA margin of 38.5%
- Expansion into oncology injectables with Kakkalur facility
- Faster ANDA approvals
- Successful US commercialization of acquired ANDAs
- On-time completion and ramp-up of Kakkalur oncology facility
- Delayed oncology API facility
- Slowed sales growth
- Micro-cap liquidity risk
FII increased stake by 0.35%, DII decreased stake by -0.12%. Promoter holding steady at 70.57%.
Indian pharma exports growing, but facing pricing pressures.
Acquired 10 approved ANDAs for injectable and ophthalmic products with an addressable market of $473.2 million.
Yes. Free Cash Flow 5Y: ₹932.15 Cr.
Next 3-6 months hinge on USFDA inspections and commercial launch of acquired products. Oncology facility ramp-up is key.
Primary Thesis Risk
USFDA regulatory risk can wipe out the entire thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Caplin Point Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Caplin Point Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CAPLIPOINT across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (20.62%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.63%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (32.74%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (19.45%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (15.56% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (21.81% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (21.93% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (923.75x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1011.97 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (70.57%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 8.29%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Caplin Point Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Caplin Point Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Caplin Point Laboratories LtdCaplin Point La...Selected✓ CAPLIPOINT • 524742 | 77/100 | ₹2516.80₹2517 | ₹20131.31₹20131.31 | 31.39Average 31.4 Average | 20.62%Excellent 20.62% Excellent | 24.63%Excellent 24.63% Excellent | 0.00Excellent 0.0 Excellent | 21.93%Excellent 21.93% Excellent | 15.56%Excellent 15.56% Excellent | 0.23% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Caplin Point Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for CAPLIPOINT — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹70.25 | ₹1838.10 | 26.2x |
| FY 2024 | ₹59.90 | ₹2500.65 | 41.7x |
| FY 2023 | ₹49.18 | ₹1356.15 | 27.6x |
| FY 2022 | ₹39.26 | ₹713.30 | 18.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Caplin Point Laboratories Ltd Dividend History
Annual cash dividends paid by CAPLIPOINT — dividend yield 0.23%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹37.99 Cr |
| FY 2024 | ₹34.17 Cr |
| FY 2023 | ₹30.32 Cr |
| FY 2022 | ₹22.69 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Caplin Point Laboratories Ltd Quarterly Performance
Latest quarterly metrics for CAPLIPOINT — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
19.45%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
19.32%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
15.56%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
21.93%
Compounded annual net profit growth over 5 years
Caplin Point Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CAPLIPOINT — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Caplin Point Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Caplin Point Laboratories Ltd (CAPLIPOINT) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Caplin Point Laboratories Ltd
About CAPLIPOINT (Caplin Point Laboratories Ltd)
Caplin Point Laboratories Ltd is a dynamic pharmaceutical company carving a niche in the global healthcare landscape. Focusing on specialized injectable products and a broad range ...of therapeutic segments, Caplin Point distinguishes itself through its commitment to innovation and affordability. Their state-of-the-art manufacturing facilities, equipped with cutting-edge technology, adhere to stringent international regulatory standards, ensuring the highest quality in every product they deliver. With a strategic emphasis on emerging markets, Caplin Point actively seeks to address unmet medical needs by providing accessible and effective pharmaceutical solutions to patients worldwide. Their dedication to research and development fuels a continuous pipeline of novel formulations, strengthening their position as a significant player in the pharmaceutical industry. Driven by a patient-centric approach, Caplin Point Laboratories manufactures a diverse portfolio encompassing various dosage forms, including sterile injectables, ophthalmics, and oral solids. This comprehensive range enables them to cater to a wide spectrum of medical conditions and patient requirements. Their expertise lies in developing and manufacturing complex generics and niche formulations, offering cost-effective alternatives without compromising on efficacy or safety. The company's vertically integrated operations, from API sourcing to finished product distribution, provide them with greater control over the supply chain, ensuring timely delivery and consistent product quality. This strategic advantage allows Caplin Point to effectively navigate the complexities of the global pharmaceutical market and maintain a competitive edge. Caplin Point Laboratories is deeply rooted in a culture of ethical business practices and sustainable growth. They consistently invest in enhancing their manufacturing capabilities, expanding their product portfolio, and strengthening their global distribution network. By forging strategic partnerships and collaborations, they aim to expand their reach and impact on global healthcare. The company's commitment to social responsibility extends beyond providing affordable medicines, actively engaging in community development initiatives and environmental stewardship. Caplin Point envisions a future where quality healthcare is accessible to all, and they are dedicated to playing a pivotal role in realizing that vision through their innovative pharmaceutical solutions and unwavering commitment to excellence.
Company Details
Key Leadership
Corporate Events
CAPLIPOINT Share Price: Frequently Asked Questions
What is the current share price of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd (CAPLIPOINT) trades at ₹2516.80 on NSE and BSE. Market cap ₹20.13K (Cr). Educational data only.
What is the P/E ratio of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd has a P/E of 31.39x vs industry average 34.89x.
What is the Bull Run score for Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd has a Bull Run score of 77/100 based on 25+ financial parameters.
Does Caplin Point Laboratories Ltd pay dividends?
Caplin Point Laboratories Ltd has a dividend yield of 0.23%. Past dividends don't guarantee future payments.
What is the ROE of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd has ROE of 20.62%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd has debt-to-equity of 0.00.
Is Caplin Point Laboratories Ltd a good investment?
Bull Run gives Caplin Point Laboratories Ltd a score of 77/100. This is not investment advice — consult a SEBI-registered advisor.